prime DX Liquid

This is an innovative assay in the field of Oncology.

The new prime DX® Liquid test consists of a panel of 1021 genes, which analyses the immunotherapy biomarkers TMB, MSI, HLA, allowing the treating physician to plan an effective treatment for the patient, including immunotherapy, chemotherapy, PARP inhibitors and compatibility of participation in clinical trials.In addition,

prime DX® Liquid, analyses genes involved in genetic predisposition to cancer, thus providing information to the physician about the likelihood of an inherited cancer syndrome.Recommended for the following cases:

• When there is not enough tissue or recent biopsy
• If the tissue quality is poor (e.g. too much bone in the sample)
• When there is a metastatic and multifocal disease
• After treatment to check patient’s response
• If the patient relapses and there is a need for molecular profiling without biopsy

Liquid Biopsy – Advantages

Tissue biopsy is the test of choice for testing the molecular profile of the tumour. Liquid biopsy is an alternative method in which free circulating genetic material (ctDNA) from the tumour in a blood sample is isolated and tested.

• Non-invasive method (blood sampling)
• Possibility of successive analyses – monitoring the progress of the disease
• Low failure rate (~3%) due to unsuitability of the material
• Better assessment of the genetic heterogeneity of the tumour

Results and Reporting